Abstract: Objective: To observe the clinical efficacy of nimodipine conjoin pulse activating injection on pretmature intracranial hemorrhage. Methods: One hundred and thirty-eight patients who had intracranial hemorrhage were randomly divided into the treatment group(n=78) and the control group(n=60). The complications were positively treated, and also the treatment group accepted nimodipine conjoin pulse activating injection. The effective rate, mortality, occurrence of hydrocephalus, peri-ventricular leucomalacia, mental retardation and cerebral palsy were observed. Results: The efficacy of the treatment group (78.1%) was better than that of the control group (55.0%) (P<0.01). The mortality and the occurrence rate of hydrocephalus, peri-ventricular leucomalacia, mental retardation and cerebral palsy of the treatment group were respectively 11.5%, 8.7%, 18.5%, 8.7% and 4.3%, which were all significantly lower than those of the control group: 25.0%, 37.7%, 37.8%, 33.0% and 17.0%(P<0.05 or P<0.01). Conclusions: Nimodipine conjoin pulse activating injection is a safe and effective method for premature intracranial hemorrhage. It cannot only reduce the mortality, but also decreases the complications and sequela.

Key words: Intracranial hemorrhages, Infant, premature, Nimodipine, Pulse activating injection